Department of Pathology, Division of Neuropathology, The Johns Hopkins Medical Institutions (JHMI), Baltimore, MD 21205, USA.
Neurosci Lett. 2011 May 2;494(3):222-6. doi: 10.1016/j.neulet.2011.03.017. Epub 2011 Mar 21.
Stem cells provide novel sources of cell therapies for motor neuron disease that have recently entered clinical trials. In the present study, we transplanted human neural stem cells (NSCs) into the ventral horn of both the lumbar (L4-L5) and cervical (C4-C5) protuberance of SOD1 G93A rats, in an effort to test the feasibility and general efficacy of a dual grafting paradigm addressing several muscle groups in the front limbs, hind limbs and the respiratory apparatus. Transplantation was done prior to the onset of motor neuron disease. Compared with animals that had received dead NSC grafts (serving as controls), rats with live NSCs grafted at the two spinal levels lived 17 days longer. Disease onset in dually grafted animals was delayed by 10 days compared to control animals. Disease duration in NSC-grafted animals was longer by 7 days compared to controls. Our results support the potential of NSC grafts at multiple levels of spinal cord as future cellular therapy for motor neuron disease.
干细胞为运动神经元疾病的细胞治疗提供了新的来源，最近这些治疗已经进入临床试验。在本研究中，我们将人神经干细胞（NSC）移植到 SOD1 G93A 大鼠的腰椎（L4-L5）和颈椎（C4-C5）隆突的腹角，以测试针对前肢、后肢和呼吸器官的多个肌肉群的双重移植方案的可行性和一般疗效。移植是在运动神经元疾病发作之前进行的。与接受死亡 NSC 移植的动物（作为对照）相比，在两个脊髓水平进行活 NSC 移植的大鼠多活了 17 天。与对照组相比，双重移植动物的疾病发作延迟了 10 天。与对照组相比，NSC 移植动物的疾病持续时间延长了 7 天。我们的研究结果支持在多个脊髓水平进行 NSC 移植作为运动神经元疾病未来细胞治疗的潜力。
